THE IMPORTANCE OF FDA APPROVAL OF TOPICAL MEDICATIONS
JEFFREY GUDIN, MD
Professor of Medicine
Department of Anesthesiology, Perioperative Medicine and Pain Management
University of Miami Miller School of Medicine
Miami, FL
OTHER RECOMMENDED VIDEOS
ADVERTISEMENT
 |
THE CHANGING PAIN MANAGEMENT LANDSCAPE
JEFFREY GUDIN, MD
|
 |
TOPICAL ANALGESICS: THE IMPORTANCE OF FDA APPROVAL
STEVEN STANOS, DO
|
 |
APPROPRIATE PATIENTS FOR TOPICAL THERAPY: IMPORTANT CONSIDERATIONS
CHARLES ARGOFF, MD
|
 |
ACP AND AAFP GUIDELINE UPDATES FOR PAIN - WHERE DO TOPICALS FIT IN?
JEFFREY GUDIN, MD
|
 |
TOPICAL ANALGESICS: UNDERSTANDING THE MOA TO MAKE PROPER TREATMENT DECISIONS
STEVEN STANOS, DO
|
 |
PROPOSED NEW LOW-DOSE ASPIRIN GUIDELINES: A REVIEW OF ORAL NSAIDS
JEFFREY GUDIN, MD
|
 |
BEST PRACTICES IN PAIN MANAGEMENT
JEFFREY GUDIN, MD
|
 |
DIFFERENTIATING RISK BETWEEN ORAL AND TOPICAL MEDICATIONS- BACKED BY SCIENCE
JEFFREY GUDIN, MD
|
 |
TOPICAL ANALGESICS: CHOOSING THE PROPER MEDICATION
JEFFREY GUDIN, MD
|
 |
THE IMPORTANCE OF FDA APPROVAL OF TOPICAL MEDICATIONS
JEFFREY GUDIN, MD
|
 |
THE CHANGING PAIN MANAGEMENT LANDSCAPE
CHARLES ARGOFF, MD
|
 |
INCORPORATING TOPICAL THERAPIES AS PART OF A MULTI- MODAL TREATMENT APPROACH
CHARLES ARGOFF, MD
|
 |
USING EVIDENCE-BASED MEDICAL MANAGEMENT WHEN CHOOSING TOPICAL THERAPIES
CHARLES ARGOFF, MD
|
 |
ASSESSMENT AND DIAGNOSIS OF THE PAIN PATIENT: EVALUATING THE WHOLE PATIENT
STEVEN STANOS, DO
|
 |
RISK MITIGATION STRATEGIES: UNDERSTANDING INTERPATIENT VARIABILITY
STEVEN STANOS, DO
|
 |
ACP/ACR/AAFP GUIDELINE UPDATES: A PERSON CENTERED APPROACH TO CARE
STEVEN STANOS, DO
|
 |
Proposed Guideline Changes for Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease (CVD)
Chris J. Kottenstette, PA-C, CPE
|
 |
NSAIDS: Understanding Common and Uncommon Risks
Chris J. Kottenstette, PA-C, CPE
|
 |
NSAIDS: Differentiating Oral vs. Topical
Chris J. Kottenstette, PA-C, CPE
|
 |
ACP/AAFP Guideline Updates for Musculoskeletal Pain
Chris J. Kottenstette, PA-C, CPE
|
 |
Safety and Efficacy of Over the Counter Products: The Importance of FDA Approval
Chris J. Kottenstette, PA-C, CPE
|
 |
Best Practices in Pain Management: Minimizing Risk through Rational Polypharmacy
Chris J. Kottenstette, PA-C, CPE
|
 |
The Changing Landscape in Pain Management
THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC
|
 |
Topical Analgesics: Updates to Clinical Guidelines
THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC
|
 |
NSAIDS: Risk Mitigation Strategies
THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC
|
 |
OTC Topical Analgesics: Cutting Through the Noise
THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC
|
 |
Best Practices in Pain Management for Frontline Clinicians
THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC
|
 |
The Expanding Role of the NP/PA in Practice
THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC
|
 |
Proper Patient Assessment, Diagnosis, and Treatment
JEREMY A. ADLER, DMSC, PA-C
|
 |
Treatment Decisions: Understanding the Rehabilitative Model vs. Palliative Model
JEREMY A. ADLER, DMSC, PA-C
|
 |
Patient Expectations and Goal Setting
JEREMY A. ADLER, DMSC, PA-C
|
 |
Topical Medications: Understanding Side Effects of Treatment
JEREMY A. ADLER, DMSC, PA-C
|
 |
Where do OTC Treatments Fit Into Practice?
JEREMY A. ADLER, DMSC, PA-C
|
 |
Future Opportunities in the Pain Management Field
JEREMY A. ADLER, DMSC, PA-C
|
 |
Importance of FDA Approval for Topical Therapies
JEREMY A. ADLER, DMSC, PA-C
|
ADVERTISEMENT